January 27, 2020 10:22 AM ESTUpdated February 2, 05:03 PM

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Natalie Grover

Reporter

AstraZeneca kicked off Monday with a flurry of good news. Apart from unveiling positive results on its stroke trial testing its clot-fighter Brilinta, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Natalie Grover

Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

US warns drugmakers against misrepresenting cost of imported products

Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study